Constant pH Molecular Dynamics Reveals pH-Modulated Binding of Two Small-Molecule BACE1 Inhibitors.

Targeting β-secretase (BACE1) with small-molecule inhibitors offers a promising route for treatment of Alzheimer's disease. However, the intricate pH dependence of BACE1 function and inhibitor efficacy has posed major challenges for structure-based drug design. Here we investigate two structurally similar BACE1 inhibitors that have dramatically different inhibitory activity using continuous constant pH molecular dynamics (CpHMD). At high pH, both inhibitors are stably bound to BACE1; however, within the enzyme active pH range, only the iminopyrimidinone-based inhibitor remains bound, while the aminothiazine-based inhibitor becomes partially dissociated following the loss of hydrogen bonding with the active site and change of the 10s loop conformation. The drastically lower activity of the second inhibitor is due to the protonation of a catalytic aspartate and the lack of a propyne tail. This work demonstrates that CpHMD can be used for screening pH-dependent binding profiles of small-molecule inhibitors, providing a new tool for structure-based drug design and optimization.

[1]  Charles L. Brooks,et al.  λ‐dynamics: A new approach to free energy calculations , 1996 .

[2]  J. Mayer,et al.  Biochemical and kinetic characterization of BACE1: investigation into the putative species‐specificity for β‐ and β′‐cleavage sites by human and murine BACE1 , 2004 .

[3]  James E Audia,et al.  Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor , 2011, The Journal of Neuroscience.

[4]  Shankar Venkatraman,et al.  Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease. , 2013, Journal of medicinal chemistry.

[5]  Takashi Sakurai,et al.  Crystal Structure of an Active Form of BACE1, an Enzyme Responsible for Amyloid β Protein Production , 2008, Molecular and Cellular Biology.

[6]  Benjamin T. Miller,et al.  Constant pH Molecular Dynamics in Explicit Solvent with Enveloping Distribution Sampling and Hamiltonian Exchange , 2014, Journal of chemical theory and computation.

[7]  Alexander D. MacKerell,et al.  Improved treatment of the protein backbone in empirical force fields. , 2004, Journal of the American Chemical Society.

[8]  Christopher R. Ellis,et al.  pH-Dependent Population Shift Regulates BACE1 Activity and Inhibition. , 2015, Journal of the American Chemical Society.

[9]  C. Brooks,et al.  Constant‐pH molecular dynamics using continuous titration coordinates , 2004, Proteins.

[10]  Wei Chen,et al.  Recent development and application of constant pH molecular dynamics , 2014, Molecular simulation.

[11]  Loriano Storchi,et al.  New and Original pKa Prediction Method Using Grid Molecular Interaction Fields , 2007, J. Chem. Inf. Model..

[12]  Adrian E Roitberg,et al.  Enhancing Conformation and Protonation State Sampling of Hen Egg White Lysozyme Using pH Replica Exchange Molecular Dynamics. , 2012, Journal of chemical theory and computation.

[13]  Jana K. Shen,et al.  Continuous Constant pH Molecular Dynamics in Explicit Solvent with pH-Based Replica Exchange. , 2011, Journal of chemical theory and computation.

[14]  Amy S. Espeseth,et al.  Discovery of aminoheterocycles as a novel beta-secretase inhibitor class: pH dependence on binding activity part 1. , 2009, Bioorganic & medicinal chemistry letters.

[15]  G. McGaughey,et al.  Beta-secretase (BACE-1) inhibitors: accounting for 10s loop flexibility using rigid active sites. , 2007, Bioorganic & medicinal chemistry letters.

[16]  C. Brooks,et al.  Constant pH molecular dynamics with proton tautomerism. , 2005, Biophysical journal.

[17]  Wolfgang Guba,et al.  β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. , 2013, Journal of medicinal chemistry.

[18]  James Andrew McCammon,et al.  Conformational Dynamics and Binding Free Energies of Inhibitors of BACE-1: From the Perspective of Protonation Equilibria , 2015, PLoS Comput. Biol..

[19]  C. Soares,et al.  Constant-pH molecular dynamics using stochastic titration , 2002 .

[20]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[21]  Sarah L. Williams,et al.  Progress in the prediction of pKa values in proteins , 2011, Proteins.

[22]  Britt-Marie Swahn,et al.  Aminoimidazoles as BACE-1 inhibitors: the challenge to achieve in vivo brain efficacy. , 2012, Bioorganic & medicinal chemistry letters.

[23]  M. Witmer,et al.  Kinetic studies on beta-site amyloid precursor protein-cleaving enzyme (BACE). Confirmation of an iso mechanism. , 2003, The Journal of biological chemistry.

[24]  C. Brooks,et al.  Constant pH molecular dynamics of proteins in explicit solvent with proton tautomerism , 2014, Proteins.

[25]  Suresh Babu,et al.  Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction. , 2012, ACS medicinal chemistry letters.

[26]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[27]  D. Schlatter,et al.  Substrate and Inhibitor Profile of BACE (β-Secretase) and Comparison with Other Mammalian Aspartic Proteases* , 2002, The Journal of Biological Chemistry.

[28]  M. Kennedy,et al.  Measuring human beta-secretase (BACE1) activity using homogeneous time-resolved fluorescence. , 2003, Analytical biochemistry.

[29]  Jana K. Shen,et al.  Charge-leveling and proper treatment of long-range electrostatics in all-atom molecular dynamics at constant pH. , 2012, The Journal of chemical physics.

[30]  J. Pandit,et al.  Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug–Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors , 2015, Journal of medicinal chemistry.

[31]  D. Case,et al.  Constant pH molecular dynamics in generalized Born implicit solvent , 2004, J. Comput. Chem..

[32]  Jana K. Shen,et al.  Thermodynamic coupling of protonation and conformational equilibria in proteins: theory and simulation. , 2012, Biophysical journal.

[33]  K. Parris,et al.  Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design. , 2015, Journal of medicinal chemistry.

[34]  R. Vassar.  BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[35]  P. Lansbury,et al.  A century-old debate on protein aggregation and neurodegeneration enters the clinic , 2006, Nature.

[36]  Lingyan Wang,et al.  Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation. , 2010, Journal of medicinal chemistry.

[37]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[38]  Franco Lombardo,et al.  Measurement of dissociation constants (pKa values) of organic compounds by multiplexed capillary electrophoresis using aqueous and cosolvent buffers. , 2008, Journal of pharmaceutical sciences.